Nomogram for Predicting the Risk of Post-Craniotomy Intracranial Infection in Patients With Brain Tumors

用于预测脑肿瘤患者开颅术后颅内感染风险的列线图

阅读:2

Abstract

BACKGROUND: This study aims to develop a nomogram to predict the risk of post-craniotomy intracranial infection (PCII) in patients with brain tumors. METHODS: Data from patients with brain tumors hospitalized between January 2021 and December 2023, encompassing personal attributes and clinical assessments, were compiled from the First Affiliated Hospital of Jinan University. Multifactorial analysis was employed to identify potential PCII risk factors. A nomogram model was crafted based on these risk factors. The model's predictive efficacy was evaluated using the concordance index (C-index), area under the receiver operating characteristic curve (AUC), and calibration curve. Additionally, PCII risk was forecasted at -3, -7, and -14 days post-surgery. RESULTS: Among 968 patients with brain tumors, 120 developed PCII post-surgery, resulting in a 12.40% incidence rate. Via multivariate Cox proportional hazards regression analysis and Akaike information criterion, nine PCII risk factors were identified, including BMI, surgical duration, preoperative albumin levels, hypertension, diabetes, indwelling drainage tube usage, subtentorial location, cerebrospinal fluid leakage, and intraoperative blood loss ≥ 400 mL. A nomogram model incorporating these predictors yielded a C-index of 0.876. The AUC values for PCII at -3, -7, and -14 days were 0.787, 0.842, and 0.873, respectively. Notably, the calibration curve illustrated close alignment between predicted and actual infection rates in patients with brain tumors at -3, -7, and -14 days. CONCLUSIONS: We developed a nomogram model to predict the occurrence of PCII in patients with brain tumors, facilitating the assessment of PCII risk in this patient population.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。